Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells

Endocrine-Related Cancer

Volumn 13, Issue 4, 2006, Pages 1237-1250

  Baradari, Viola ^a   Huether, Alexander ^a   Höpfner, Michael ^a   Schuppan, Detlef ^b   Scherübl, Hans ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c VIVANTES KLINIKUM AM URBAN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; CASPASE 3; CYCLIN D1; DNA FRAGMENT; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OCTREOTIDE; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; SOMATOSTATIN DERIVATIVE; TRICHOSTATIN A;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; GASTROINTESTINAL TUMOR; HUMAN; HUMAN CELL; IC 50; NEUROENDOCRINE TUMOR; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN INDUCTION; SIDE EFFECT; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BENZAMIDES; BUTYRATES; CARCINOID TUMOR; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; CYCLIN D1; ENZYME INHIBITORS; GASTROINTESTINAL NEOPLASMS; HISTONE DEACETYLASES; HISTONES; HORMONES; HUMANS; HYDROXAMIC ACIDS; NEUROENDOCRINE TUMORS; OCTREOTIDE; PYRIDINES; SOMATOSTATIN;

EID: 33846813964     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01249     Document Type: Article

References (61)

1. Acharya MR, Sparreboom A, Venitz J & Figg WD 2005 Rational development of histone deacetylase inhibitors as anticancer agents: a review. Molecular Pharmacology 68 917-932.
2. Baroni MG, Cavallo MG, Mark M, Monetini L, Stoehrer B & Pozzilli P 1999 Beta-cell gene expression and functional characterisation of the human insulinoma cell line CM. Journal of Endocrinology 161 59-68.
3. Bhalla K & List A 2004 Histone deacetylase inhibitors in myelodysplastic syndrome. Best Practice & Research. Clinical Haematology 17 595-611.
4. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA & Richnon VM 2002 The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulated thioredoxin-binding protein-2, and down-regulate thioredoxin. PNAS 99 11700-11705.
5. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA & Grever MR 1999 Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94 1401-1408.
6. 1 arrest in fibroblasts. Journal of Cellular Physiology 202 87-99.
7. Decker T & Lohmann-Matthes ML 1988 A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. Journal of Immunological Methods 115 61-69.
8. Della Ragione F, Criniti V, Della Pietra V, Borriello A, Oliva A, Indaco S, Yamamoto T & Zappia V 2001 Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Letters 499 199-204.
9. Duan H, Heckman CA & Boxer LM 2005 Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Molecular and Cellular Biology 5 1608-1619.
10. Eickhoff B, Ruller S, Laue T, Kohler G, Stahl C, Schlaak M & van der Bosch J 2000 Trichostatin A modulates expression of p21waf1/cip1, Bcl-xL, ID1, ID2, ID3, CRAB2, GATA-2, hsp86 and TFIID/TAFII31 mRNA in human lung adenocarcinoma cells. Biological Chemistry 381 107-112.
11. Evers BM, Ishizuka J, Townsend CM Jr & Thompson JC 1994 The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Annals of the New York Academy of Sciences 15 393-406.
12. Fournel M, Trachy-Bourget MC, Yan PT, Kalita A, Bonfils C, Beaulieu C, Frechette S, Leit S, Abou-Khalil E, Woo SH et al. 2002 Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Research 62 4325-4330.
13. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H. Wang HG, Atadja P & Bhalla K 2003 Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Molecular Cancer Therapeutics 2 971-984.
14. Gillies RJ, Didier N & Denton M 1986 Determination of cell number in monolayer cultures. Analytical Biochemistry 159 109-113.
15. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P & Bhalla K 2004 Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Research 64 2580-2589.
16. Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D & Paraskeva C 1993 Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. International Journal of Cancer 55 498-505.
17. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C & Brancolini C 2003 Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). Journal of Biological Chemistry 278 12579-12589.
18. Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG & Schuppan D 2002 The histone-deacetylase inhibitor trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. Journal of Hepatology 36 233-240.
19. Höpfner M, Sutter AP, Huether A, Ahnert-Hilger G & Scherübl H 2004 A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine. BMC Cancer 4 23.
20. Johnstone RW 2002 Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Reviews. Drug Discovery 1 287-299.
21. Johnstone RW & Licht JD 2003 Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4 13-18.
22. Kim YB, Ki SW, Yoshida M & Horinouchi S 2000 Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. Journal of Antibiotics 53 1191-1200.
23. Kouraklis G & Theocharis S 2002 Histone deacetylase inhibitors and anticancer therapy. Current Medicinal Chemistry. Anti-Cancer Agents 2 477.
24. Kouzarides T 1999 Histone acetylases and deacetylases in cell proliferation. Current Opinion in Genetics & Development 9 40-48.
25. Kramer OH, Göttlicher M & Heinzel T 2001 Histone deacetylase as a therapeutic target. Trends in Endocrinology and Metabolism: TEM 12 294-300.
26. Lallemand F, Courilleau D, Buquet-Fagot C, Atfi A, Montagne MN & Mester J 1999 Sodium butyrate induces G2 arrest in the human breast cancer cells MDA-MB-231 and renders them competent for DNA rereplication. Experimental Cell Research 247 432-440.
27. Lin HY, Chen CS, Lin SP, Weng JR & Chen CS 2006 Targeting histone deacetylase in cancer therapy. Medicinal Research Reviews 26 397-413.
28. Maaser K, Höpfner M, Jansen A, Weisinger G, Gavish M, Kozikowski AP, Weizman A, Carayon P, Riecken EO, Zeitz M et al. 2001 Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. British Journal of Cancer 85 1771-1780.
29. Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S & Grant S 2004 The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Research 64 2590-2600.
30. Marks PA, Richon VM & Rifkind RA 2000 Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. Journal of the National Cancer Institute 92 1210-1216.
31. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T & Kelly WK 2001 Histone deacetylases and cancer: causes and therapies. Nature Reviews. Cancer 1 194-202.
32. Marks PA, Miller T & Richon VM 2003 Histone deacetylases. Current Opinion in Pharmacology 3 344-351.
33. McBain JA, Eastman A, Nobel CS & Mueller GC 1997 Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochemical Pharmacology 53 1357-1368.
34. McIntyre A, Gibson PR & Young GP 1993 Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut 34 386-391.
35. Monneret C 2005 Histone deacetylase inhibitors. European Journal of Medicinal Chemistry 40 1-13.
36. Natoni F, Diolordi L, Santoni C & Gilardini Montani MS 2005 Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochimica et Biophysica Acta 1745 318-329.
37. 2-M transition. Biochemical and Biophysical Research Communications 310 267-273.
38. Öberg K 1994 Expression of growth factors and their receptors in neuroendocrine gut and pancreatic tumors, and prognostic factors for survival. Annals of the New York Academy of Science 733 46-55.
39. Öberg K 1996 Neuroendocrine gastrointestinal tumours. Annals of Oncology 7 453-463.
40. Öberg K 2001 Chemotherapy and biotherapy in the treatment of neuroendocrine tumors. Annals of Oncology 12 111-114.
41. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA & Johnstone RW 2003 Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Research 63 4460-4471.
42. Richon VM, Sandhoff TW, Rifkind RA & Marks PA 2000 Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. PNAS 97 10014-10019.
43. Roh MS, Kim CW, Park BS, Kim GC, Jeong JH, Kwon HC, Suh DJ, Cho KH, Yee SB & Yoo YH 2004 Mechanism of histone deacetylase inhibitor trichostatin A induced apoptosis in human osteosarcoma cells. Apoptosis 9 583-589.
44. Rosato RR & Grant S 2003 Histone deacetylase inhibitors in cancer therapy. Cancer Biology & Therapy 2 30-37.
45. Rosato RR, Wang Z, Gopalkrishnan RV, Fisher PB & Grant S 2001 Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). International Journal of Oncology 19 181-191.
46. 2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Letters 237 143-154.
47. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T & Nakanishi O 1999 A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. PNAS 96 4592-4597.
48. Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, Kisanuki T, Tamura Y, Satone A, Ide W, Hashimoto I et al. 2001 Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathology 18 109-114.
49. Scherübl H, Faiss S & Zeitz M 2003 Neuroendocrine tumors of the gastrointestinal tract- diagnosis and therapy. Deutsche Medizinische Wochenschrift 128 81-83.
50. Schwartz B, Avivi-Green C & Polak-Charcon S 1998 Sodium butyrate induces retinoblastoma protein dephosphorylation, p16 expression and growth arrest of colon cancer cells. Molecular and Cellular Biochemistry 188 21-30.
51. Singh TR, Shankar S & Srivastava RK 2005 HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24 4609-4623.
52. Staiano-Coico L, Steinberg M & Higgins PJ 1990 Epidermal cell-shape regulation and subpopulation kinetics during butyrate-induced terminal maturation of normal and SV40-transformed human keratinocytes: epithelial models of differentiation therapy. International Journal of Cancer 46 733-738.
53. Sutter AP, Maaser K, Grabowski P, Bradacs G, Vormbrock K, Höpfner M, Krahn A, Heine B, Stein H, Somasundaram R et al. 2004 Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1. Journal of Hepatology 41 799-807.
54. Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, Ishikawa T, Tahara E & Yasui W 2000 Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. International Journal of Cancer 88 992-997.
55. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG & Baylin SB 2002 A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genetics 31 141-149.
56. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I & Koeffler HP 2004 Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 10 1141-1149.
57. Van Lint C, Emiliani S & Verdin E 1996 The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation. Gene Expression 5 245-254.
58. 1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth & Differentiation: The Molecular Biology Journal of the American Association for Cancer Research 9 465-474.
59. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I & Coombes RC 2001 Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 7 971-976.
60. Weckbecker G, Raulf F, Tolcsvai L & Bruns C 1996 Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo. Digestion 57 22-28.
61. Yamashita Y, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S & Sugimachi K 2003 Histone deacetylase inhibitor trichostatin A induces cell- cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. International Journal of Cancer 103 572-576.